2025-05-29 - Analysis Report
Okay, here's a report summarizing the provided data for Johnson & Johnson (JNJ), compared to the S&P 500 (VOO), with analysis:

## Johnson & Johnson (JNJ) Stock Analysis

**Ticker:** JNJ
**Company Overview:** Johnson & Johnson is a global healthcare company that develops and manufactures pharmaceuticals, medical devices, and consumer packaged goods.

### 1. Relative Performance

*   **JNJ Cumulative Return:** 19.37%
*   **VOO (S&P 500) Cumulative Return:** 82.09%
*   **Performance Gap:** -62.72%
*   **Relative Deviation (Range: 17.5 to -76.3):** 14.5 (Indicates JNJ's performance is near the lower end of its historical deviation range compared to VOO)

#### Alpha, Beta Analysis Table

| Year       | CAGR   | MDD    | Alpha  | Beta | Cap(B) |
|------------|--------|--------|--------|------|--------|
| 2015-2017  | 28.0%  | 56.4%  | -1.0%  | 0.0  | 272.6  |
| 2016-2018  | 10.0%  | 10.8%  | -7.0%  | 0.0  | 258.6  |
| 2017-2019  | 20.0%  | 10.8%  | -9.0%  | 0.7  | 300.5  |
| 2018-2020  | 14.0%  | 59.8%  | -12.0% | 0.5  | 333.0  |
| 2019-2021  | 28.0%  | 59.8%  | -26.0% | 0.3  | 371.1  |
| 2020-2022  | 4.0%   | 61.2%  | -2.0%  | 0.3  | 393.3  |
| 2021-2023  | -19.0% | 61.2%  | -35.0% | 0.4  | 359.6  |
| 2022-2024  | -30.0% | 61.2%  | -47.0% | 0.3  | 342.3  |
| 2023-2025  | -7.0%  | 69.6%  | -37.0% | 0.2  | 366.8  |

**Analysis:** JNJ has significantly underperformed the S&P 500 over the period examined. The negative alpha values indicate underperformance relative to the market risk-adjusted return. The beta values are generally low, suggesting that JNJ's price is less volatile than the market.  The increasing negative alpha trend in recent years suggests increasing underperformance.  The large MDD (Maximum Drawdown) figures indicate significant potential losses during these periods. CAGR has been declining, suggesting lower growth rates recently.

### 2. Recent Price Action

*   **Current Price:** 152.43
*   **Previous Close:** 153.25
*   **Change:** -0.54
*   **5-Day Moving Average:** 152.10
*   **20-Day Moving Average:** 152.03
*   **60-Day Moving Average:** 155.85

**Analysis:** The current price is slightly below the previous close, indicating a minor price decrease. The 5-day and 20-day moving averages are close to each other, suggesting a period of price consolidation or sideways movement in the short term. The 60-day moving average is higher than the shorter-term averages, indicating that the stock price has been trending downwards recently.

### 3. Technical Indicators

*   **Market Risk Indicator (MRI):** 0.37 (Low Risk)
*   **RSI:** 41.93 (Approaching oversold territory)
*   **PPO:** 0.24
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.37)
*   **Recent (20-Day) Relative Deviation Change:** 1.6 (+, indicating short-term upward movement)
*   **Expected Return (%):** -180.2% (Significant underperformance expected relative to the S&P 500 over the long term)

**Analysis:** The MRI indicates a low-risk environment. RSI near 42 suggests the stock is approaching oversold territory, potentially indicating a buying opportunity. The positive change in recent relative deviation suggests a short-term upward trend compared to the S&P 500, but is not very high. However, the extremely negative expected return is concerning and warrants further investigation. The hybrid signal is giving a buy signal for 80% of available cash. The recent price change of -0.54, while small, could contribute to short-term volatility, especially if this trend continues.

### 4. Recent News & Significant Events

*   **2025-05-25:** Johnson & Johnson (JNJ) has recently made headlines due to major business developments, regulatory changes, or market events.
*   **2025-05-27:** Analysts are discussing Johnson & Johnson's (JNJ) recent performance and its outlook in the context of industry trends and global economic factors.
*   **2025-05-26:** Johnson & Johnson (JNJ)'s stock has shown notable volatility, influenced by recent news, earnings reports, or executive actions.
*   **2025-05-28:** Market experts highlight both risks and opportunities for Johnson & Johnson (JNJ), advising investors to monitor recent news and company announcements.

**Analysis:** Recent news highlights potential volatility and the importance of staying informed about company-specific events, regulatory changes, and analyst perspectives. The mixed tone suggests a period of uncertainty or transition for the company.

### 5. Recent Earnings Analysis

| 날짜       | EPS  | 매출      |
|------------|------|-----------|
| 2025-04-23 | 4.57 | 21.89 B$  |
| 2024-10-23 | 1.12 | 22.47 B$  |
| 2024-07-25 | 1.95 | 22.45 B$  |
| 2024-05-01 | 1.35 | 21.38 B$  |
| 2025-04-23 | 1.35 | 21.38 B$  |

**Analysis:** The provided data suggests fluctuating earnings and revenue. The EPS varies from 1.12 to 4.57, indicating variability in profitability. Revenue also fluctuates but remains in a relatively narrow range.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-03-31   | $21.89B    | 66.40%        |
| 2024-12-31   | $22.52B    | 68.35%        |
| 2024-09-30   | $22.47B    | 69.01%        |
| 2024-06-30   | $22.45B    | 69.40%        |
| 2024-03-31   | $21.38B    | 69.55%        |

**Capital and Profitability:**

| Quarter      | Equity     | ROE   |
|--------------|------------|-------|
| 2025-03-31   | $78.11B    | 14.08%|
| 2024-12-31   | $71.49B    | 4.80% |
| 2024-09-30   | $70.16B    | 3.84% |
| 2024-06-30   | $71.54B    | 6.55% |
| 2024-03-31   | $70.02B    | 4.65% |

**Analysis:** Revenue has been relatively stable. Profit margins are high but show a slightly decreasing trend. Equity has increased, and ROE (Return on Equity) has fluctuated significantly, with a recent increase to 14.08%.

### 7. Overall Assessment

Johnson & Johnson (JNJ) has underperformed the S&P 500 significantly. While the MRI indicates low market risk and the RSI suggests the stock may be approaching oversold territory, the negative expected return and recent price weakness are concerning. The recent news suggests potential volatility and the need to monitor company-specific developments. The earnings and revenue data shows fluctuations. The long-term historical negative alpha indicates underperformance relative to its market risk.

**Recommendation:** Given the mixed signals, a cautious approach is advised. While the Hybrid signal is giving a buy signal, the extremely negative expected return warrants a deeper investigation before investing. Monitoring upcoming news and earnings reports will be critical.
